Trial Profile
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2024
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 06 Mar 2024 Planned End Date changed from 1 Oct 2020 to 5 Mar 2025.
- 27 Sep 2021 Status changed to discontinued, according to Results published in the Clinical Cancer Research
- 27 Sep 2021 Primary endpoint has not been met (overall survival defined as time from randomization to death of any cause) , according to Results published in the Clinical Cancer Research